Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus

American Journal of Medicine

Volumn 118, Issue 12 SUPPL., 2005, Pages 10-15

  Betteridge, John ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Diabetes; Dyslipidemia; Fibrates; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DYSLIPIDEMIA; HEALTH CARE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 28844468067     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.09.013     Document Type: Conference Paper

References (26)

1. A.F. Amos, D.J. McCarty, P. Zimmet The rising global burden of diabetes and its complications estimates and projections to the year 2010 Diabet Med. 14 suppl 5 1997 S1 S85
2. S.M. Haffner, K. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med. 339 1998 229 234
3. H. Miettinen, S. Lehto, V. Salomaa FINMONICA Myocardial Infarction Register Study Group Impact of diabetes on mortality after the first myocardial infarction Diabetes Care. 21 1998 69 75
4. M. Laakso, S. Lehto, I. Penttila, K. Pyorala Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes Circulation. 88 1993 1421 1430
5. International Diabetes Federation Diabetes and Cardiovascular Disease Time to Act 2001 International Diabetes Federation Brussels
6. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet. 352 1998 837 853
7. M.R. Taskinen Controlling lipid levels in diabetes Acta Diabetol. 39 suppl 2 2002 S29 S34
8. J.R. Downs, M. Clearfield, S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS [Air Force/Texas Coronary Atherosclerosis Prevention Study] JAMA. 279 1998 1615 1622
9. F.M. Sacks, M.A. Pfeffer, L.A. Moye Cholesterol and Recurrent Events Trial investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med. 335 1996 1001 1009
10. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial Lancet. 360 2002 7 22
11. C.P. Cannon, E. Braunwald, C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med. 350 2004 1495 1504
12. The Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) Lancet. 344 1994 1383 1389
13. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med. 339 1998 1349 1357
14. P.S. Sever, B. Dahlöf, N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) a multicentre randomised controlled trial Lancet. 361 2003 1149 1158
15. J. Shepherd The West of Scotland Coronary Prevention Study a trial of cholesterol reduction in Scottish men Am J Cardiol. 76 1995 113C 117C
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 285 2001 2486 2497
17. G. De Backer, E. Ambrosioni, K. Borch-Johnsen Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Executive summary European guidelines on cardiovascular disease prevention in clinical practice Eur Heart J. 24 2003 1601 1610
18. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens. 21 2003 1011 1053
19. K. Pyorala, T.R. Pedersen, J. Kjekshus, Ó Faergeman, A.G. Olsson, G. Thorgeirsson Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care. 20 1997 614 620
20. R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes a randomised placebo-controlled trial Lancet. 361 2003 2005 2016
21. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 288 2002 2981 2997
22. V.G. Athyros, A.A. Papageorgiou, B.R. Mercouris Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study Curr Med Res Opin. 18 2002 220 228
23. H.B. Rubins, S.J. Robins, D. Collins Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med. 341 1999 410 418
24. H.B. Rubins, S.J. Robins, D. Collins Diabetes, plasma insulin, and cardiovascular disease subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Arch Intern Med. 162 2002 2597 2604
25. H.M. Colhoun, D.J. Betteridge, P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) multicentre randomised placebo-controlled trial Lancet. 364 2004 685 696
26. S.M. Haffner Dyslipidemia management in adults with diabetes Diabetes Care. 27 suppl 1 2004 S68 S71